Effects of DA D1 and D2 antagonists on the sensitisation to the motor effects of morphine in mice. 2002

Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
Area de Psicobiología, Facultad de Psicología, Universitat de València, Aptdo. 22109, Valencia 46071, Spain.

Acute morphine administration produces hyperactivity in mice and repeated treatment induces an enhancement of this effect. In this experiment, we study the sensitisation to the hyperactivity induced by intermittent morphine administration (40 mg/kg) and the effects of dopamine (DA) antagonists on this phenomenon. Animals received three injections, separated by 48 h, and after each injection, their activity was registered between 30 and 60 min. In Experiment 1, animals were divided into two groups, which received saline and morphine (S-S-M) or only morphine (M-M-M). In Experiment 2, animals were divided into 12 groups. Half, which was designed to study the effects of DA antagonists on the acquisition of morphine sensitisation, received morphine plus 0.125, 0.25, or 0.5 mg/kg SCH 23390 or raclopride in the two first administrations and only morphine in the third (M+SCH-M+SCH-M; M+R-M+R-M). The other groups, designed to study the effects of DA antagonists on the expression of morphine sensitisation, received morphine in the two first administrations and morphine plus DA antagonists in the last injection (M-M-M+SCH; M-M-M+R). Intermittent morphine administration produces greater hyperactivity than acute morphine. DA D1 antagonists reduce acquisition and block expression of sensitisation, while DA D2 antagonists only affect expression with the intermediate and high dose. These results support the implication of DA in the behavioural sensitisation of morphine in mice.

UI MeSH Term Description Entries
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009294 Narcotics Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. Analgesics, Narcotic,Narcotic Analgesics,Narcotic,Narcotic Effect,Narcotic Effects,Effect, Narcotic,Effects, Narcotic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017447 Receptors, Dopamine D1 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES. Dopamine D1 Receptors,Dopamine-D1 Receptor,D1 Receptors, Dopamine,Dopamine D1 Receptor,Receptor, Dopamine-D1
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018492 Dopamine Antagonists Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. Dopamine Antagonist,Dopamine Blocker,Dopamine Receptor Antagonist,Dopamine Receptor Antagonists,Dopaminergic Antagonist,Dopaminergic Antagonists,Antagonists, Dopamine,Antagonists, Dopamine Receptor,Antagonists, Dopaminergic,Dopamine Blockers,Antagonist, Dopamine,Antagonist, Dopamine Receptor,Antagonist, Dopaminergic,Blocker, Dopamine,Blockers, Dopamine,Receptor Antagonist, Dopamine,Receptor Antagonists, Dopamine
D065127 Dopamine D2 Receptor Antagonists Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. Dopamine D2 Antagonist,Dopamine D2 Receptor Antagonist,Dopamine D2 Antagonists,Receptor Antagonists, Dopamine D2,Antagonist, Dopamine D2,Antagonists, Dopamine D2,D2 Antagonist, Dopamine,D2 Antagonists, Dopamine

Related Publications

Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
January 1987, Proceedings of the Western Pharmacology Society,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
March 1999, Psychopharmacology,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
April 2000, Behavioral neuroscience,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
May 2001, Naunyn-Schmiedeberg's archives of pharmacology,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
March 1994, Behavioral and neural biology,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
July 1994, Pharmacology & toxicology,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
July 1988, Pharmacology, biochemistry, and behavior,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
January 1993, Pharmacology & toxicology,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
January 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience,
Amparo Serrano, and Maria A Aguilar, and Carmen Manzanedo, and Marta Rodríguez-Arias, and José Miñarro
April 2016, European journal of pharmacology,
Copied contents to your clipboard!